CPA
PRLD icon

Capital Performance Advisors’s Prelude Therapeutics PRLD Stock Holding History

Capital Performance Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8
Closed -$17 – 2036
2024
Q3 		$17 Buy
+8
New +$37 ﹤0.01% 2864

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Capital Performance Advisors's PRLD Position: Q4 2024 in Review

Capital Performance Advisors sold out of Prelude Therapeutics (PRLD) in Q4 2024, closing a stake of 8 shares — an estimated $17 sold.

Capital Performance Advisors first reported a position in PRLD in Q3 2024 and held it in 1 quarter. The position peaked at $17 in Q3 2024. 62 funds tracked by Wall St. Rank hold PRLD as of Q4 2024.

  • Capital Performance Advisors reported no remaining Prelude Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 8 Prelude Therapeutics shares in Q4 2024, an estimated $17.
  • Capital Performance Advisors first reported a position in Prelude Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Prelude Therapeutics position peaked at $17 in Q3 2024.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.